Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Family Medicine | Internal Medicine | Allergy | Neurology | Pathology | Pharmacy | Journal

Back to Journal Articles

Early Immunotherapy May Benefit Autoimmune Epilepsy

Last Updated: March 28, 2012.

 

Patients who responded to immunotherapy began treatment significantly earlier than nonresponders

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Patients suspected of having autoimmune epilepsy that fails to respond to anti-epileptic drugs may benefit from early immunotherapy, according to a study published online March 26 in the Archives of Neurology.

WEDNESDAY, March 28 (HealthDay News) -- Patients suspected of having autoimmune epilepsy that fails to respond to anti-epileptic drugs may benefit from early immunotherapy, according to a study published online March 26 in the Archives of Neurology.

Amy M.L. Quek, M.B.B.S., from the Mayo Clinic in Rochester, Minn., and colleagues retrospectively identified 32 patients suspected of having autoimmune epilepsy (presence of neural autoantibodies, inflammatory cerebrospinal fluid, or signs of inflammation on magnetic resonance imaging). All of the patients had partial seizures and 81 percent had failed treatment with at least two anti-epileptic drugs. Immunotherapy was started in 27 patients.

After a median of 17 months, the researchers found that 22 patients (81 percent) reported improvement after immunotherapy and 18 were free of seizures. Responders had initiated immunotherapy significantly earlier from seizure onset than nonresponders (4 versus 22 months). All patients with neural autoantibodies against the voltage-gated potassium channel complex (56 percent of patients) reported some benefit of immunotherapy.

The study "on autoimmune epilepsy is another reminder that we need to broaden our concept of symptomatic chronic epilepsy from the structural realm into more dynamic processes not limited to acute inflammatory or infectious pathologies (e.g., meningitis or encephalitis)," Gregory K. Bergey, M.D., from Johns Hopkins Hospital in Baltimore, Md., writes in an accompanying editorial.

Several authors disclosed financial relationships with pharmaceutical and medical device companies. Two authors are named as inventors on patents pertaining to neuromyelitis optica.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Invasive Strategy Ups Survival in Myotonic Dystrophy 1 Next: Moderate Drinking Cuts Mortality in MI Survivors

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2013
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.